Exelixis (EXEL) Profit After Tax (2010 - 2026)
Exelixis' (EXEL) quarterly Profit After Tax came in at $210.5 million in Q2 2026, up 31.86% year-on-year from $159.6 million in Q2 2025, and down 13.93% quarter-over-quarter from $244.5 million in Q1 2026.
Exelixis (EXEL) Profit After Tax (2010 - 2026) Analysis & Trends
Exelixis' Profit After Tax history runs 17 years deep, the most recent figure standing at $210.5 million for Q2 2026.
- On a quarterly basis, Profit After Tax rose 31.86% year-over-year to $210.5 million in Q2 2026; TTM through Apr 2026 was $833.4 million, a 29.5% increase from a year earlier, with the FY2026 full-year figure at $782.6 million, up 50.13% from the prior year.
- Profit After Tax slipped to $210.5 million in Q2 2026 per EXEL's latest filing, from $244.5 million in the prior quarter.
- Across five years, Profit After Tax topped out at $244.5 million in Q1 2026 and bottomed at -$30.2 million in Q4 2022.
- The 5-year median for Profit After Tax is $85.5 million (2023), against an average of $112.0 million.
- Across the five-year window, Profit After Tax plunged 131.71% in 2022 and soared 11232.66% in 2024, its largest moves.
- Year by year, Profit After Tax stood at -$30.2 million in 2022, then surged by 383.43% to $85.5 million in 2023, then jumped by 37.95% to $118.0 million in 2024, then jumped by 64.09% to $193.6 million in 2025, then increased by 8.72% to $210.5 million in 2026.
- Per Business Quant, the three latest EXEL Profit After Tax figures stand at $210.5 million (Q2 2026), $244.5 million (Q1 2026), and $193.6 million (Q4 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,538.84 Bn | 65,538.56 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.72 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 469.46 Bn | 464.67 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 122.69 Bn | 115.45 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 70.41 Bn | 61.65 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.84 Bn | 62.84 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.10 Bn | 50.91 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Alnylam Pharmaceuticals | 37.48 Bn | 34.47 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Exelixis | 14.49 Bn | 13.71 Bn | 590.86 Mn | 210.47 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Apr 3, 2026 | 210.47 Mn |
| Jan 2, 2026 | 244.53 Mn |
| Oct 3, 2025 | 193.58 Mn |
| Jul 4, 2025 | 184.85 Mn |
| Apr 4, 2025 | 159.62 Mn |
| Jan 3, 2025 | 139.86 Mn |
| Sep 27, 2024 | 117.97 Mn |
| Jun 28, 2024 | 226.12 Mn |
| Mar 29, 2024 | 37.32 Mn |
| Dec 29, 2023 | 85.52 Mn |
| Sep 29, 2023 | 1.04 Mn |
| Jun 30, 2023 | 81.18 Mn |
| Mar 31, 2023 | 40.03 Mn |
| Dec 30, 2022 | -30.17 Mn |
| Sep 30, 2022 | 73.21 Mn |
| Jul 1, 2022 | 70.67 Mn |
| Apr 1, 2022 | 68.57 Mn |
| Dec 31, 2021 | 95.17 Mn |
| Oct 1, 2021 | 38.20 Mn |
| Jul 2, 2021 | 96.09 Mn |